Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters








Language
Year range
1.
Acta cir. bras ; Acta cir. bras;36(11): e361107, 2021. ilus, tab, graf
Article in English | LILACS, VETINDEX | ID: biblio-1456243

ABSTRACT

Purpose To evaluate the effect of ergosterol combined with risedronate on fracture healing. Methods Sixty male Sprague Dawley fracture model rats were assigned into group A (n=20), group B (n=20), and group C (n=20) at random. All rats were fed by gavage until their sacrifice as it follows: group A with ergosteroside and risedronate, group B with risedronate, and group C with saline solution. At weeks 2 and 4, 10 rats of each group were sacrificed. Healing effect and bone tissue changes in the fractures site were assessed by using hematoxylin and eosin stain histology. Enzyme-linked immunosorbent assay was used to detect the expression of serum bone morphogenetic protein-2 (BMP-2), bone morphogenetic protein-7 (BMP-7), and vascular endothelial growth factor (VEGF). Reverse transcriptase polymerase chain reaction was applied to detect the expression of osteoprotegerin (OPG) mRNA, osteocalcin (OCN) mRNA and core-binding factor subunit-?1 (CBF-?1) mRNA. Results In terms of serum BMP-2, BMP-7, and VEGF expression at weeks 2 and 4 after gavage, group A < group B < group C (P<0.05). At week 4 after gavage, serum VEGF expression in the three groups harbored positive relationship with serum BMP-2 and BMP-7 expression (P<0.05). Regarding serum OPG, OCN and CBF-?1 mRNA expression at weeks 2 and 4 after gavage, group A

Subject(s)
Male , Animals , Rats , Fracture Healing/drug effects , Ergosterol/analysis , Vascular Endothelial Growth Factor A , Osteoprotegerin/isolation & purification , Risedronic Acid/analysis , Reverse Transcriptase Polymerase Chain Reaction
2.
Mem. Inst. Oswaldo Cruz ; 113(10): e180174, 2018. graf
Article in English | LILACS | ID: biblio-1040582

ABSTRACT

Farnesyl diphosphate synthase/geranylgeranyl diphosphate synthase (FPPS/GGPPS) is a key enzyme in the synthesis of isoprenic chains. Risedronate, a bisphosphonate containing nitrogen (N-BP), is a potent inhibitor of blood stage Plasmodium. Here, we show that P. falciparum parasites overexpressing FPPS/GGPPS are more resistant to risedronate, suggesting that this enzyme is an important target, and bisphosphonate analogues can be used as potential antimalarial drugs.


Subject(s)
Animals , Plasmodium falciparum/drug effects , Plasmodium falciparum/enzymology , Farnesyltranstransferase/biosynthesis , Risedronic Acid/pharmacology , Antimalarials/pharmacology , Plasmodium falciparum/growth & development , Reference Values , Drug Resistance , Blotting, Western , Analysis of Variance , Farnesyltranstransferase/analysis , Risedronic Acid/analysis , Antimalarials/analysis
SELECTION OF CITATIONS
SEARCH DETAIL